Santen, Inc. Phase 3 Study Meets Primary Endpoint For The Treatment Of Non-Infectious Posterior Segment Uveitis (NI-PSU)
4/4/2014 8:22:06 AM
EMERYVILLE, Calif.--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double-masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
Help employers find you! Check out all the jobs and post your resume.
comments powered by